MindMed

Corporate Presentation

August 2025

Disclaimer

This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed”, the “Company”, “we”, “our” or “us) solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities. Any trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of MindMed. Any amounts are in USD unless otherwise noted. MindMed’s securities have not been approved or disapproved by the Securities and Exchange Commission (the "SEC") or by any state, provincial or other securities regulatory authority, nor has the SEC or any state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense.

Cautionary Note Regarding Forward-Looking Statements

This Presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of applicable securities laws and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may", “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential”, “continue”, “budget”, “scheduled”, “forecasts”, “intends”, “anticipates”, “projects” or the negative thereof or similar variations. Forward-looking statements in this Presentation include, but are not limited to, statements regarding the anticipated design, timing, progress and results of our investigational programs for MM120, a proprietary, pharmaceutically optimized form of lysergide D-tartrate (including the anticipated topline readouts for the Voyage, Panorama and Emerge studies), MM402, also referred to as R(-)-MDMA, and any other product candidates; the success and timing of our development activities; the success and timing of our planned clinical trials; our ability to meet the milestones set forth herein; the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approvals; our beliefs regarding potential benefits of our product candidates; opinions of potential providers regarding our product candidates, if approved and commercialized; our ability to maximize operational efficiencies through our trial designs; strategies to address drug class methodological considerations; our cash runway funding operations into 2027 based on our current operating plan and anticipated research and development milestones and at least 12 months beyond first Phase 3 topline data readout in GAD; our pre-launch strategy; the potential commercial opportunity for MM120, if approved, including total addressable market; the potential delivery model for MM120, if approved; the potential for the markets that we are anticipating to access and protection of our intellectual property.

There are numerous risks and uncertainties that could cause actual results, plans and objectives to differ materially from those expressed in forward-looking statements, including history of negative cash flows, limited operating history, incurrence of future losses, availability of additional capital, compliance with laws and regulations, difficulty associated with research and development, risks associated with clinical trials or studies, heightened regulatory scrutiny, early stage product development, clinical trial risks, regulatory approval processes, novelty of the psychedelic inspired medicines industry, our ability to maintain effective patent rights and other intellectual property protection for our product candidates, our expectations regarding the size of the eligible patient populations for our lead product candidates, if approved and commercialized; our ability to identify third-party treatment sites to conduct our trials and our ability to identify and train appropriate qualified healthcare practitioners to administer our treatments; the pricing, coverage and reimbursement of our lead product candidates, if approved and commercialized; the rate and degree of market acceptance and clinical utility of our lead product candidates, in particular, and controlled substances, in general; as well as those risk factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 under headings such as “Special Note Regarding Forward-Looking Statements,” and “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov.

Any forward-looking statement made by MindMed in this Presentation is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this Presentation as a result of new information, future events, changes in expectations or otherwise.

Cautionary Note Regarding Regulatory Matters

The United States federal government regulates drugs through the Controlled Substances Act. MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate and MM402, or R(-)-MDMA, is our proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). Lysergide and MDMA are Schedule I substances under the Controlled Substances Act. While the Company is focused on programs using psychedelic or hallucinogenic compounds and non-hallucinogenic derivatives of these compounds, including in its MM120, MM402 and other product candidates, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is a neuro-pharmaceutical drug development company and does not deal with psychedelic or hallucinogenic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

Market and Industry Data

This Presentation includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article. MindMed does not make any representation as to the accuracy of such information.

MindMed: Transformational Innovation for Brain Health

Strategic Focus on GAD and MDD

The two largest drivers of psychiatric disease burden

Late-Stage Pipeline

MM120 ODT: lead clinical program in three Phase 3 studies



Comprehensive Intellectual Property Strategy

MM120 ODT patents issued covering pharmaceutical formulation, methods of manufacturing and treatment

Experienced Management Team

Proven track record in developing and commercializing novel CNS therapies

Strong Financial Position

Cash, cash equivalents and investments of $237.9 million as of June 30, 2025

Cash runway expected to extend into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD[1]

Three Phase 3 readouts anticipated in 2026 + potential billion-dollar commercial opportunities in GAD and MDD

1. The Company's cash, cash equivalents and investments of $237.9 million as of June 30, 2025, expected to fund operations into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD, based on our current operating plan and anticipated R&D milestones.

GAD: generalized anxiety disorder; MDD: major depressive disorder; ODT: orally disintegrating tablet

2025
On Track and Executing

ANTICIPATED MILESTONES

Voyage

MM120-300 for GAD
Phase 3 topline readout 1H 2026

Panorama

MM120-301 for GAD
Phase 3 topline readout 2H 2026

Emerge

MM120-310 for MDD
Phase 3 topline readout 2H 2026

Strong Execution Driving Upcoming Milestones



1. The Company's cash, cash equivalents and investments of $237.9 million as of June 30, 2025, expected to fund operations into 2027 and at least 12 months beyond first Phase 3 topline data readout in GAD, based on our current operating plan and anticipated R&D milestones.

GAD: generalized anxiety disorder; MDD: major depressive disorder; APA: American Psychiatric Association; ODT: orally disintegrating tablet; U.K. MHRA: United Kingdom Medicines and Healthcare Products Regulatory Agency

Advancing Our Pipeline with Broad Therapeutic Potential



1. Full trial details and clinicaltrials.gov links available at mindmed.co/clinical-digital-trials/
2. Studies in exploration and/or planning stage.

LSD: lysergide; ODT: orally disintegrating tablet; R(-)-MDMA: rectus-3,4-methylenedioxymethamphetamine

Critical Gaps in Care Demand Innovation

GAD

26 million U.S. adults live with GAD[1]

Last FDA approval in 2007

50% of patients failed by first-line pharmacological treatments[2]

>50-70% Overlap

Co-occurring MDD and GAD is associated with increases in mean annual per patient inpatient visits, office visits, emergency department visits, annual drug costs, and total medical costs[7,8]

MDD

41 million U.S. adults live with MDD[1]

2/3 do not achieve remission after 1st line therapy[3,4]

Patients who receive treatment:
30% failed by 2+ lines of therapy[5,6]

Desired Future State of Treatment

- **Fast onset**
- **Single intermittent administration**
- **Favorable tolerability**
- **High remission rates**
- **Durable response**
- **Restores neural pathways**

1. Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI International and current U.S. Census data and internal company estimates; 2. Ansara ED. Management of treatment-resistant generalized anxiety disorder. Ment Health Clin. 2020 Nov 5;10(6):326-334; 3. Kolovos S, et al. The effect of treatment as usual on major depressive disorder: a meta-analysis. J Affect Disord. 2017;210:72-81; 4. Rush AJ, et al; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242; 5. Zhdanava M, et al. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. J Clin Psychiatry. 2021 Mar 16;82(2):20m13699; 6. McIntyre RS, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023 Oct;22(3):394-412; 7. Kessler RC, et al. Epidemiol Psychiatry Sci 2015; 24:210–226; 8. Armbrecht E, et al. J Multidiscip Healthc. 2021 Apr 23;14:887-896.

GAD: generalized anxiety disorder; MDD: major depressive disorder

Psychedelics: A Welcome Breakthrough for Providers

% of Surveyed Providers[1] Agree



Availability of psychedelics for GAD and MDD will change my approach to treatment



I expect psychedelic treatments to radically transform the treatment of GAD and MDD

1. Psychiatrists and Psychiatry Nurse Practitioners
2. Proprietary MindMed Primary Market Research – Key Customer Perceptions Among Spravato® Providers and GAD Prescribers (February 2024). Total Non-Spravato® Providers (n=125), Spravato® Providers (n=50).
3. Spravato® Providers: recommended, referred or prescribed Spravato® treatment and monitored or administered Spravato® treatment, personally or someone in her/his clinic or office.

GAD: generalized anxiety disorder; MDD: major depressive disorder; TRD: Treatment Resistant Depression

MindMed

MM120 ODT
Lysergide D-tartrate

Program Overview

Clinical Rationale and Mechanism of Action



Robust Phase 3 MM120 Development Program Aiming for Broad Label

Aligned clinical trial designs across indications maximize operational efficiencies

Generalized Anxiety Disorder (GAD)

Voyage
MM120-300

Primary Endpoint: HAM-A at Week 12

n=200[1,2]
(1:1 randomization)

MM120 ODT vs. Placebo

- **Part A:** 12-week DB, RCT
- **Part B:** 40-week Extension with OL Treatment

Initiated 4Q2024

Panorama
MM120-301

n=250[1,2]
(2:1:2 randomization)

MM120 ODT vs. Placebo (including 50 µg control)

- **Part A:** 12-week DB, RCT
- **Part B:** 40-week Extension with OL Treatment

Initiated 1Q2025

Major Depressive Disorder (MDD)

Emerge
MM120-310

Primary Endpoint: MADRS at Week 6

n=140[2]
(1:1 randomization)

MM120 ODT vs. Placebo

- **Part A:** 12-week DB, RCT
- **Part B:** 40-week Extension with OL Treatment

Initiated 2Q2025

Name TBA
MM120-311

Design TBA

1. Studies will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) which allows for an increase of sample size up to 50% to maintain statistical power.
2. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols.

DB: double blind; HAM-A: Hamilton Anxiety Rating Scale; MADRS: Montgomery-Åsberg Depression Rating Scale; ODT: orally disintegrating tablet; OL: open-label; RCT: randomized controlled trial

MM120 Phase 2b Efficacy and Durability Support GAD Phase 3 Trial Plans[1,3]

Comparative Effect Sizes in GAD



Maximum effect size d=0.81 more than double the standard of care[1,2,3]

Rapid and durable response after single administration[3]

Rapid	1.8-point reduction in CGI-S within 24 hours (p<0.0001)
Durable	21.9-point improvement on the HAM-A at Week 12 (p=0.003)
Response & Remission	48% of participants in remission at Week 12[5]
Limited Adverse Event (AE) Burden	Favorable tolerability with most AEs on dosing day
Standalone Drug Effect	Observed drug effect without accompanying psychotherapy

1. Study MMED008 internal study documents and calculations. Comparisons to standard of care/other drug classes based on historical comparison not head-to-head comparison trial; 2. HAM-A scores based on ANCOVA LS Mean. in Study MMED008. Effect size based on post hoc calculation using LS Mean change between group and pooled standard deviation of week 12 HAM-A scores between groups; 3. Based on 100 µg dose group; 4. RB Hidalgo, J Psychopharmacol. 2007 Nov;21(8):864-72; 5. p-values not calculated for remission rates between groups.

Cohen's d: a standardized effect size measuring the difference between two group means; CGI-S: Clinical Global Impressions – Severity; GAD: generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale

MM120 Phase 2b Showed Statistically & Clinically Significant Improvements on Anxiety and Depression Symptoms[1,2]

Primary Outcome: HAM-A Change from Baseline



Change from Baseline[2]
- Week 12: -21.9 points

Improvement over Placebo[2]
- Week 12: -7.7 pts, p=0.003

MADRS Change from Baseline



Change from Baseline[2,3]
- Week 12: -18.7 points

Improvement over Placebo[2,3]
- Week 12: -6.4 points, p<0.01

*p<0.05; **p≤0.01; ***p≤0.001

1. Source: Study MMED008 internal study documents and calculations. Full analysis set population.
2. Based on 100 µg dose group.
3. Based on observed MADRS score at each timepoint.

µg: microgram; HAM-A: Hamilton Anxiety Rating Scale; MADRS: Montgomery-Åsberg Depression Rating Scale NOTE: Significance achieved despite study not being powered for these pairwise comparisons.

MM120 Phase 2b Produced Profound Changes in GAD Severity[1]

HAM-A Severity & Clinical Symptoms

Very Severe
Symptoms are incapacitating

Severe (≥24)
Symptoms are severe and persistent or result in severe distress or marked impairment in functioning

Moderate (15-23)
Symptoms are more frequent, with moderate distress or limited interference with usual activities

Mild (8-14)
Symptoms are infrequent, with no impairment and no more than mild distress

Remission (≤7)
Symptoms are absent, insignificant, or clearly due to causes other than anxiety

Median HAM-A Through Week 12



HAM-A Response and Remission at Week 12[2]



1. Source: Study MMED008 internal study documents and calculations. Full analysis set population.
2. Response is a 50% or greater improvement on HAM-A score; Remission is a HAM-A score of ≤7; p-values not calculated.

µg: microgram; HAM-A: Hamilton Anxiety Rating Scale

MM120 Phase 2b was Well-tolerated with Mostly Expected Transient, Mild-to-Moderate Adverse Events on Dosing Day[1]

Favorable tolerability profile

- Virtually all (99%) adverse events (AEs) were mild-to-moderate in severity
- Minimal (2.5%) treatment emergent AEs (TEAEs) led to study withdrawal
- No drug-related serious AEs (SAEs)[2]

No SAEs related to study drug

- Only SAE was in 50 µg dose group and deemed unrelated [2]
- AE profile consistent with historical studies and drug class

No suicidal behavior or suicidality signal[3]

- No suicidal or self-injurious behavior
- No indication of increased suicidality or suicide-related risk
- ≤2 participants per arm reported suicidal ideation during the study

1. Source: Study MMED008 internal study documents and calculations. Safety population.
2. One serious adverse event (SAE) was observed in the 50 µg dose group: panic attack on study day 98 that was deemed not related to treatment.
3. Suicidality assessment based on reported adverse events.

MM120 for GAD | Two Complementary Pivotal Phase 3 Study Designs[1]



1. Studies will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) to maintain statistical power. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols.

GAD: generalized anxiety disorder; GAD-7: diagnostic tool used to screen for and assess the severity of generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale; ODT: orally disintegrating tablet

MM120 for MDD | Phase 3 Study Design[1]

PHASE 3 STUDY[1]

Emerge

MM120-310

Part A
12 Week Randomized, Double-Blind

Single Dose

n=70 — **MM120 ODT 100 µg**

n=70 — **Placebo**

Primary Endpoint
MADRS at Week 6

Part B
40 Week Extension with Opportunity for Open-Label Treatment

Potential treatment if MADRS≥20

Up to four open-label doses of MM120 ODT 100 µg

Follow-up Observation
PHQ-9 (ePRO): biweekly
MADRS (central rater): monthly or when PHQ-9≥10

Potential Treatment
Eligible for open-label treatment if MADRS≥20

MM120-311

[Design TBA]

1. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols.

MADRS: Montgomery-Åsberg Depression Rating Scale; MDD: Major Depressive Disorder; ODT: orally disintegrating tablet; PHQ-9: a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression; TBA: to be announced

Regulatory Elements Supporting MM120 ODT NDA Filing Requirements



1. Study MMED008 internal study documents and calculations. Comparisons to standard of care/other drug classes based on historical comparison not head-to-head comparison trial.

GAD: generalized anxiety disorder; NDA: new drug application

MindMed

MM120 ODT
LSD D-tartrate

Commercial Framework

Large, Identified, Accessible Opportunity for MM120 ODT

High Unmet Need

Significant Limitations of Existing Treatments

Poor efficacy, tolerability, and persistence

Poor Efficacy

- Slow onset of effect[1]
- Low response and remission rates[2-4]
- Low Rx persistence[5]

Poor Tolerability

- Weight gain[6]
- Sexual dysfunction[6]
- Tolerance and dependence[7]

~50% **Discontinue SSRIs in first 4 mos. in GAD[8,9]**

~22% **Rx persistence at 12 mos. in MDD[5]**

Paradigm Shifting Clinical Profile

MM120 ODT: Potential Best-In-Class Therapy

Sustained clinical response from a single administration[10]

Rapid onset of effect

High response rates

High remission rates

Durable response

Intermittent dosing potentially reduces the risk of adverse long-term effects

Efficient Go To Market Strategy

Existing Referral and Administration Infrastructure

Identifiable HCPs and patients suffering from the burden of inadequate treatment

Based on claims data

~7,000
Psychiatrists see >50% of likely MM120 ODT patients[11]

Anticipate scalable delivery model in diverse care settings

Positive practice economics anticipated to expand sites of care

1. Bandelow B et al. *World J Biol Psychiatry*. 2008;9(4):248-312. 2. Ansara ED. *Ment Health Clin*. 2020;10(6):326-334. 3. Fagan HA, Baldwin DS. *Expert Rev Neurother*. 2023;23(6):535-548. 4. Garakani A et al. *Front Psychiatry*. 2020;11:595584. 5. Keyloun KR et al. *CNS Drugs*. 2017;31(5):421-432. 6. Cascade E et al. *Psychiatry (Edgemont)*. 2009;6(2):16-18. 7. National Institute for Health and Care Excellence. Anxiety disorders. Quality standard QS53. February 6, 2016. Accessed July 10, 2025. https://www.nice.org.uk/guidance/qs53
8. Bull SA et al. *Ann Pharmacother*. 2002;36:578-584. 9. Berger A et al. *BMC Psychiatry*. 2011;11:193. 10. Jacobsen PL et al. American Psychiatric Association Annual Meeting. May 4-8, 2024. New York, NY; 11. Based on internal company estimates.

GAD: generalized anxiety disorder; HCP: healthcare provider; MDD: major depressive disorder; ODT: orally disintegrating tablet; Rx: prescription; SSRI: selective serotonin-reuptake inhibitor

MM120 ODT Clinical Dosing Paradigm with Translatability to Efficient Real-World Delivery[1,2]

15-30 minutes (time to onset)

MM120 ODT dissolves in less than 5 seconds

Hour 1-6

Transient drug effects, such as visual, emotional and physical effects, vary from person to person

Hours 2-3: drug effect reaches maximum intensity

Hours 4-6: drug effect starts to resolve

Hour 5-8

Hour 5: DSM will evaluate patient hourly with an end-of-session checklist to determine when the patient can leave safely

5–8-hour duration offers an optimal window for emotional processing and a gentle, predictable, return to baseline

Hour 6+ and post session

Usual sense of perception is restored

Normal activities can resume the next day, including driving

Efficient single-visit model with full-session reimbursement streamlines administrative burden

- Patients are supported by Dosing Session Monitors (DSMs), healthcare professionals who passively observe and offer comfort care such as assistance with food or restrooms breaks.
- Psychotherapy is not offered or required but may be added outside a dosing session based on a decision between a provider and patient to support individual goals and needs.

1. Dosing and monitoring paradigm based on Phase 3 clinical protocols
2. Existing coding systems could potentially be applied or be changed for MM120. Reimbursement and coding for MM120 have yet to be established.

ODT: orally disintegrating tablet

Positioned to Leverage Existing Delivery Infrastructure, Practice Patterns & Reimbursement Pathways

	Activity	Stakeholder	Reimbursement/Coding[3]
	**Evaluation & Prescribing**	Office-based or Telehealth Prescriber[1]	**Medical Benefit** CPT-I E&M Code (992XX)
	**Session Delivery**	Site of delivery HCP[2] to monitor session	**Medical Benefit** CPT-III Code[4] (0820T/0821T/0822T) *or* CPT-I Service Codes (992XX + 994XX)
	**MM120 ODT**	Pharmacy	**Pharmacy Benefit** J Code & Dispensing Fee

1. HCP that is licensed to prescribe medications to patients.
2. HCP that is licensed to practice, which may include physicians, clinical psychologists, nurse practitioners, nurses, licensed clinical social workers, licensed family and marriage therapists and others.
3. Existing coding systems could potentially be applied or be changed for MM120. Reimbursement and coding for MM120 have yet to be established.
4. The currently available CPT-III codes (0820T, 0821T, 0822T) describes the in-person continuous monitoring of a psychedelic medication therapy session.

CPT: Current Procedural Terminology; ODT: orally disintegrating tablet

Financial Summary & Upcoming Milestones

Cash, Cash Equivalents & Investments

$237.9 million

as of June 30, 2025

Credit Facility

Up to $120 million

($42 million outstanding)

as of June 30, 2025

Shares Outstanding

75.8 million

as of June 30, 2025

Second Quarter 2025 Operating Expenses

$40.9 million

- R&D - $29.8 million
- G&A - $11.1 million

Three Phase 3 topline readouts expected in 2026
Potential billion-dollar commercial opportunities in both GAD and MDD

MM120 ODT

	Key Milestones	Anticipated Timing
Voyage	GAD Phase 3 topline data	1H 2026
Panorama	GAD Phase 3 topline data	2H 2026
Emerge	MDD Phase 3 topline data	2H 2026

MindMed

Nasdaq: MNMD

MindMed

Appendix

MM120 for GAD | Phase 3 Study Design Leverages Phase 2b Results[1]



Voyage

- MM120 ODT 100 µg (n=100)[2]
- Placebo (n=100)[2]

MM120-300
200 participants (1:1)[2]

Panorama

- MM120 ODT 100 µg (n=100)[2]
- Placebo (n=100)[2]
- MM120 ODT 50 µg (n=50)[2]

MM120-301
250 participants (2:1:2)[2]

MM120-300 & 301 | Parts A & B

Primary Endpoint: HAM-A at Week 12

SELECT ENTRY CRITERIA

- Men and Women
- Ages 18-74
- Diagnosis of GAD
- HAM-A ≥20

KEY SECONDARY ENDPOINTS

- HAM-A at Week 1
- CGI-S at Day 2
- Time to retreatment / inefficacy

PART B ENDPOINTS

- Safety of repeated treatment
- Time to retreatment / inefficacy
- Average treatments per year
- Response to retreatment

1. Source: Study MM120-300 and Study MM120-301 internal study documents.
2. Study will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) allowing for up to 50% more subjects in each arm to maintain statistical power. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols.

µg: microgram; CGI-S: Clinical Global Impressions - Severity; GAD: generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale; ODT: orally disintegrating tablet

Strategies Addressing Key Drug Class Methodological Considerations

Expectancy Bias & Functional Unblinding

- Independent central raters blinded to treatment and visit number for primary outcome measure
- Dose-response in Phase 2b across “functionally active” doses
- Complementary studies with multiple ‘functionally masking’ arms
- Pre- and post-dose expectancy assessment (participants)
- Post-dose (participant) and rating (raters) blinding assessment
- Drug effect isolated from psychotherapeutic intervention

Cardiovascular Safety

- Collection of ECGs in Phase 3 Clinical Trials
- Dedicated TQT study in parallel with Phase 3

Adverse Event Collection

- Collection of all AEs, including “positive” and MOA-related
- Frequent assessment to define time course for resolution of drug effects

AE: adverse event; ECG: electrocardiogram; MOA: mechanism of action; TQT: thorough QT

MM120 | Multiple Layers of Intellectual Property and Protection



1. Section 505 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355.

PK: pharmacokinetic; PD: pharmacodynamic